Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT00487071 |
| Other study ID # |
CRE-2006.274 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
N/A
|
| First received |
June 13, 2007 |
| Last updated |
February 12, 2014 |
| Start date |
August 2006 |
| Est. completion date |
February 2014 |
Study information
| Verified date |
February 2014 |
| Source |
Chinese University of Hong Kong |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee |
| Study type |
Interventional
|
Clinical Trial Summary
The aim of this pilot study is to evaluate the efficacy and safety of anal fistula plug in
the management of high-type anal fistulae among Hong Kong Chinese patients.
Description:
An anal fistula is an abnormal communication between the anal or rectal lumen and the
perianal skin. Anal fistulae are described according to the level at which they transgress
the anal sphincter. If the internal opening begins above the anal sphincter then the fistula
is described as 'high'. Traditional surgery for high-type anal fistulae often requires
staged operations with fistulotomy and seton insertion. The surgery usually results in large
and deep wounds which can take months to heal. Moreover, risk of faecal incontinence is
inevitable because part of the anal sphincter is divided during the surgery.
The Surgisis® anal fistula plug is a minimally invasive and sphincter-preserving alternative
to traditional fistula surgery. It is a newly developed biomaterial made from complex
collagen obtained from pigs - animals that have a collagen structure almost identical to
that of human tissue. During manufacturing of the plug, living cells are removed by special
processes to help ensure that no transmittable diseases are present in the tissue. The plug
is a conical device and is placed by drawing it through the fistula tract and suturing it in
place. As pig collagen is so similar to human collagen, the plug, once implanted,
incorporates naturally over time into the human tissue (human cells and tissues will 'grow'
into the plug), thus facilitating the closure of the fistula. Preliminary clinical data from
USA showed a high fistula closure rate of 87%. The anal fistula plug can also avoid
protracted postoperative wound care and minimise the risk of faecal incontinence.
We would like to carry out a pilot study, the aim of which is to evaluate the efficacy and
safety of this new anal fistula plug in the management of high-type anal fistulae. This is
believed to be the first study of its kind in Hong Kong.
Patients with high-type anal fistulae confirmed by MRI will be recruited into this study.
Patients with previous history of fistula surgery, patients with Crohn's disease, and
patients with known allergy to porcine material will be excluded. EUA + anal fistula plug
will be performed. Outcome measures include fistula healing rate, recurrence rate, and
morbidity. Follow-up MRI will be arranged at 3 months and 6 months after the operation to
objectively evaluate the healing of the fistulae.
